Skip to content
Screener

Evolus EOLS Business Segments — In-process research and development

Similar metrics at other companies

NuScale Power logo
SMRIn-process research and development
$16.9M0.0%
Neurocrine Biosciences logo
NBIXReportable Segment — Acquired in-process research and development
$21.2M+21,100%
Mirum Pharmaceuticals, Inc. logo
MIRMReportable Segment — Acquired in-process research and development
$16.44M
Roivant Sciences logo
ROIVReportable Segment — Acquired in-process research and development
$0
BioCryst Pharmaceuticals logo
BCRXReportable Segment — Acquired in-process research and development
$0
Eli Lilly logo
LLYReportable Segment — Acquired in-process research and development
$2.78B+1,703%

Other financials

Income statement

See full
Revenue$84.1M+21.2%
Gross profit$57.2M+26.2%
Operating income-$4.5M+55.5%
Net income-$8.1M+53.0%
EPS (diluted)-$0.12+55.6%

Balance sheet

See full
Cash & equivalents$45.2M-26.8%
Total debt$164.8M+12.3%
Total equity-$30.9M-65.7%
Total assets$248.0M+8.4%

Cash flow

See full
Operating cash flow-$3.6M+85.5%
CapEx$50.0K-92.7%
Free cash flow-$3.6M+85.7%

Valuation

See full
Market cap$500M+31.0%
Enterprise value$619.64M+32.8%
P/S1.6×+0.2×

Profitability

See full
Gross margin66.7%-0.4pp
Operating margin-13.7%-1.9pp
Net margin-10.9%-3.7pp
FCF margin-9.6%-3.6pp

Returns & leverage

See full
Return on equity-472.6%-1,534pp
Debt / equity22.2×
Current ratio1.7×-0.6×

Where this comes from

Reported directly by Evolus in its filing.

Tagged under the XBRL concept eols:ResearchAndDevelopmentInProcess1.

The source filing: Evolus’s 10-K, filed March 3, 2026.

Filed
Mar 3, 2026, 5:01 PM EST
Fiscal year
FY2025
Accession
0001628280-26-014001
Line itemYear Ended December 31, 2025Year Ended December 31, 2024Year Ended December 31, 2023
Operating expenses:
Selling, general and administrative220,786198,025164,944
Research and development9,5769,1726,556
In-process research and development8,869
Revaluation of contingent royalty obligation payable to Evolus Founders(6,381)7,1764,257
Depreciation and amortization4,3452,3422,178
Restructuring costs1,443
Total operating expenses229,769216,715186,804

Item 8. Financial Statements and Supplementary Data.

FAQ

What is Evolus's business segments — in-process research and development?
Evolus (EOLS) reported business segments — in-process research and development of $0 in Q4 2025.
What is the long-term trend for Evolus's business segments — in-process research and development?
Over 3 years (2022 to 2025), Evolus's business segments — in-process research and development has grown at a -100.0% compound annual growth rate (CAGR), from $2M to $0.
What does business segments — in-process research and development mean?
This represents the value assigned to research and development projects that are currently in progress and have not yet reached technological feasibility. It reflects the investment in future product pipelines or intellectual property that may generate future economic benefits. Tracking this helps investors evaluate the company's commitment to long-term innovation and future growth potential.

Ask your AI about Evolus's business segments — in-process research and development.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude